Intervention

comparative genomic hybridization

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting1

Common conditions4

Lead sponsors shown6

Clinical trials

6 shown

Molecular Predictors of Cancer in Patients at High Risk of Lung CancerNCT00898313 · 2003-12-01

Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate CancerNCT00967954 · 2008-09-01

Studying Genes in Blood and Lung Fluid Samples From Patients With Chronic Obstructive Pulmonary Disease With or Without a Previous Diagnosis of Lung Cancer or With Asthma Treated With Budesonide and FormoterolNCT00569712 · 2007-01-01

S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and FluorouracilNCT00897091 · 2006-07-01

Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast CancerNCT00070278 · 2005-01-01

Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy ParticipantsNCT00899028 · 2001-05-01

Common conditions

Lung Cancer3 Breast Cancer2 Precancerous Condition1 Prostate Cancer1

Leading sponsors

British Columbia Cancer Agency1 Cambridge University Hospitals NHS Foundation Trust1 Cancer Research UK1 SWOG Cancer Research Network1 Vanderbilt University Medical Center1 Vanderbilt-Ingram Cancer Center1

Trial status mix

COMPLETED3

UNKNOWN2

RECRUITING1

Phase mix

NA1

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.